Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options

Chatterjee, Maitrayee; Anju, C P; Biswas, Lalitha; Kumar, Vivek; Mohan, C. Gopi; Biswas, Raja

doi:10.1016/j.ijmm.2015.11.004

Cited by 252 publications

(178 citation statements)

References 144 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Antibiotic therapies are widely used for treating infectious diseases (16). Previous studies have indicated that P. aeruginosa is the most common bacterial isolate in burn wards in Tehran, Iran (17,18).…”

Section: Discussionmentioning

confidence: 99%

The Prevalence of Aminoglycoside-Modifying Enzyme Genes Among Pseudomonas aeruginosa Strains Isolated From Burn Patients

Kashfi

Hashemi

Eslami

et al. 2016

Arch Clin Infect Dis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Prevalence of Aminoglycoside-Modifying Enzyme Genes Among Pseudomonas aeruginosa Strains Isolated From Burn Patients

Kashfi

Hashemi

Eslami

et al. 2016

Arch Clin Infect Dis

View full text Add to dashboard Cite

show abstract

“…Piperacillin is a beta-lactam that inhibits cell wall synthesis [30]; tobramycin is an aminoglycoside that binds to the prokaryote ribosome and inhibits protein synthesis [31]; and ciprofloxacin is a fluoroquinolone that binds DNA gyrase and inhibits DNA synthesis [32]. We chose to study these 3 antibiotics because of their common use in the clinical setting to treat P. aeruginosa infections [29], their diverse mechanisms of action, and their well-studied resistance mechanisms [33]. Adaptive evolution for 20 days to these drugs individually resulted in 1-drug-resistant mutants denoted as PIP piperacillin, tobramycin, and ciprofloxacin, respectively, compared to their initial levels.…”

Section: Adaptive Evolution Of P Aeruginosa To Sequences Of Antibioticsmentioning

confidence: 99%

History of Antibiotic Adaptation Influences Microbial Evolutionary Dynamics During Subsequent Treatment

Yen

Papin

2016

Preprint

View full text Add to dashboard Cite

Antibiotic regimens often include the sequential changing of drugs to limit the development and evolution of resistance of bacterial pathogens. It remains unclear how history of adaptation to one antibiotic can influence the resistance profiles when bacteria subsequently adapt to a different antibiotic. Here, we experimentally evolved Pseudomonas aeruginosa to six 2-drug sequences. We observed drug order-specific effects, whereby adaptation to the first drug can limit the rate of subsequent adaptation to the second drug, adaptation to the second drug can restore susceptibility to the first drug, or final resistance levels depend on the order of the 2-drug sequence. These findings demonstrate how resistance not only depends on the current drug regimen but also the history of past regimens. These orderspecific effects may allow for rational forecasting of the evolutionary dynamics of bacteria given knowledge of past adaptations and provide support for the need to consider the history of past drug exposure when designing strategies to mitigate resistance and combat bacterial infections. Author summaryBacteria readily adapt to their environments and can develop ways to survive and grow in the presence of antibiotics. While many studies have investigated how bacteria evolve to become resistant to single drugs, it is unclear how adaptation to other drugs and environments in the past affect the way bacteria adapt to new drugs and environments. In this study, we allowed bacteria in a laboratory setting to adapt to three different antibiotics. We first exposed wild-type susceptible bacteria to high concentrations of the three antibiotics individually and then exposed these populations to each of the other drugs. By tracking the levels of resistance to all three drugs in all of the treatments, we identified cases in which past adaptation to one treatment influenced subsequent evolutionary dynamics with regard to both phenotypes (levels of resistance) and genotypes (genes that became mutated). Additionally, by allowing bacterial isolates originating from human patients to adapt to the three drugs, we recapitulated a subset of the adaptation history-dependent evolutionary dynamics. Overall, this study sheds light on how adaptation history in PLOS Biology | https://doi.org/10.1371/journal

show abstract

“…Thus, it is possible that a mechanism, not efflux pump related, is inhibited by B. sempervirens extract. Antibiotic potentiation can be reached by compounds that are interfering with other mechanisms of the bacterial cell that not involve drug resistance mechanisms, such as quorumsensing, virulence activation, biofilm formation, adherence to the host tissues, 33 etc. Bacterial biofilms are particularly problematic since they become even more resistant to most available antibiotics.…”

Section: Fractionation Of Active Extract Of Buxus Sempervirensmentioning

confidence: 99%

Antibiotic adjuvants from Buxus sempervirens to promote effective treatment of drug-resistant Staphylococcus aureus biofilms

et al. 2016

View full text Add to dashboard Cite

Plants have been long scrutinized in the quest for new antibiotics, but no strong antibiotic molecule was ever found. Evidences exist that most phytochemicals have a regulatory or adjuvant effect on other antibacterial compounds, thus promoting a greater therapeutic effect. The current study assessed twenty-eight plants from different families for their antibacterial activity and as adjuvants in antibiotic therapy against Staphylococcus aureus, including methicillin-resistant S. , respectively. Non-antibacterial plants were assessed in combination with ampicillin, oxacillin, ciprofloxacin, erythromycin and tetracycline by a modified disc diffusion test. Methanolic extracts of Acacia dealbata, Prunus spp. plants, Centaurea nigra, Eupatorium cannabium and Buxus sempervirens showed a potentiating effect mostly of ciprofloxacin, erythromycin and tetracycline. B. sempervirens was selected for its potentiating activity and applied against S. aureus biofilms. B.sempervirens (1 g L -1 ) was able to cause an 88% reduction of S. aureus within 1 h exposure. Further phytochemical investigation of B. sempervirens allowed to identify betulinic acid as a major component, together with other triterpenoids. Betulinic acid and other common terpernoids -lupeol, betulin, hederagenin, ursolic acid and oleanolic acid, were tested for antibacterial and antibiotic-potentiating activities. Among the tested compounds, oleanolic acid and ursolic acid -were highlighted, showing MIC of 62.5 and 15.6 mg L -1 , respectively, against S. aureus. Additionally, oleanolic acid showed synergism when combined with tetracycline and erythromycin and caused biofilm reductions of 70, 81 and 85% when applied at ½ MIC, MIC and 2 × MIC, respectively. IntroductionTwo major circumstances have accentuated the quest for new antibacterial agents and alternative therapies in the last decades. Primarily, because microbes, due to their incredible and innate adaptability, seem to have at least equal chances for survival as scientists and pharmaceutical industries develop methods to kill them. 3 Multidrug-resistant (MDR) bacteria are responsible for a large number of nosocomial but also community-acquired infections and are spreading all over the globe. 4 Additionally, the limitation of our current arsenal of effective antibiotics accompanied by the lack of new antimicrobial alternatives are prompting the beginning of the "post-antibiotic era", which threats all the achievements of modern medicine.Since the beginning of mankind plants were undoubtedly the most important source of therapeutic remedies with an enormous range of applications. The earliest records of natural products were depicted from Mesopotamia (2600 B.C.) and included oils from cypress (Cupressus sempervirens) and myrrh (Commiphora species), which are still used today to treat coughs, colds and inflammation. 5 Many plant extracts and their phytochemical constituents are known to have antimicrobial activities. 6 However, it can be rapidly established that this effort of finding individual active anti...

show abstract

Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options

Cited by 252 publications

References 144 publications

The Prevalence of Aminoglycoside-Modifying Enzyme Genes Among Pseudomonas aeruginosa Strains Isolated From Burn Patients

The Prevalence of Aminoglycoside-Modifying Enzyme Genes Among Pseudomonas aeruginosa Strains Isolated From Burn Patients

History of Antibiotic Adaptation Influences Microbial Evolutionary Dynamics During Subsequent Treatment

Antibiotic adjuvants from Buxus sempervirens to promote effective treatment of drug-resistant Staphylococcus aureus biofilms

Contact Info

Product

Resources

About